[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536603":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":23,"locations":7,"responsibleParty":33,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":53,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":7},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DEVICE","Biobsy from kidney","using tyrosine kinase inhibitors particulary imatinib in ttt CML patients",[14],"drug , tyrosine kinase inhibitors particulary imatinib in ttt CML patients",[16,20],{"name":17,"affiliation":18,"role":19},"Ahmed Ramadan","Assist","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":5,"role":22},"Mohamed Ramadan","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"sahar mohamed gad, third","CONTACT","01007531866","sahargad22397@gmail.com",{"name":30,"role":26,"phone":31,"phoneExt":7,"email":32},"Mohamad Ramadan Abd_Elhamied, first","01097510010","drmuhamadramadan@yahoo.com",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Sahar Mohammed Gad","doctor","100536603","chronic-kidney-disease-patient-in-chronic-myloied-leukemia-100536603",false,"NCT06266975","Chronic Kidney Disease Patient in Chronic Myloied Leukemia","Inclusion Criteria:1\\_ Chronic myloid leukemia patiants who diagonised by biopsy , 2\\_ CBC.\n\n\\-\n\nExclusion : 1\\_pts known to have CKD before diagnosed of CML. 2- known Diabetic pts 3-imaging suggestive CKD etiology rather than CML effect eg.PKD,renal stones,chronic pyelonephritis","ALL","18 Years","75 Years",{"count":47,"type":48},40,"ESTIMATED","OBSERVATIONAL","To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .",[52],"Chronic Myeloid Leukemia in Remission","NOT_YET_RECRUITING","2024-02-16",{"date":56,"type":57},"2024-02-20","ACTUAL",{"date":59,"type":48},"2024-02",{"date":61,"type":48},"2026-11",{"name":35,"class":6}]